Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
17.22
+0.12 (0.70%)
Jul 26, 2024, 4:30 PM EDT - Market closed
Entrada Therapeutics Revenue
Entrada Therapeutics had revenue of $59.12M in the quarter ending March 31, 2024, with 134.05% growth. This brings the company's revenue in the last twelve months to $162.87M, up 544.79% year-over-year. In the year 2023, Entrada Therapeutics had annual revenue of $129.01M.
Revenue (ttm)
$162.87M
Revenue Growth
+544.79%
P/S Ratio
3.93
Revenue / Employee
$1,024,358
Employees
159
Market Cap
639.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 129.01M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Community Health Systems | 12.52B |
National Research | 147.42M |
Surmodics | 142.96M |
Avid Bioservices | 139.91M |
Arcturus Therapeutics Holdings | 124.53M |
Allogene Therapeutics | 65.00K |
TRDA News
- 4 weeks ago - Entrada Therapeutics Announces $100 Million Registered Direct Offering - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy - GlobeNewsWire
- 7 weeks ago - Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 6 months ago - Entrada Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA - PRNewsWire